Form 4: Enzo Biochem Director Sells Shares Post-Merger

Enzo Biochem Director Steven J. Pully disposed of all his shares and restricted stock units following the company's merger, receiving $0.70 per share in cash.

Summary

• Steven J. Pully, a Director of Enzo Biochem Inc. (ENZB), reported the disposition of 239,992 shares of common stock.
• The disposition occurred on August 20, 2025, as a result of the merger between Enzo Biochem Inc. and Bethpage Merger Sub, Inc., a wholly-owned subsidiary of Bethpage Parent, Inc.
• At the effective time of the merger, each share of Enzo Biochem's common stock was canceled and converted into the right to receive $0.70 in cash, without interest and less any applicable withholding taxes.
• The disposed amount included 142,897 Restricted Stock Units (RSUs) and 79,365 shares of Common Stock.
• RSUs held by Board members also converted to cash based on the $0.70 per share merger consideration.
• Following the transaction, Steven J. Pully's beneficial ownership in Enzo Biochem Inc. is 0 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as the merger has been completed, providing a cash exit for shareholders at the agreed-upon price. However, the company is no longer publicly traded, which could be seen as a negative for those who wished to remain shareholders.

Positives

• Shareholders, including the reporting person, received a cash consideration of $0.70 per share for their common stock and RSUs.
• The completion of the merger provides a definitive exit for shareholders at the agreed-upon price.

Negatives

• Enzo Biochem Inc. is no longer a publicly traded entity, becoming a wholly-owned subsidiary of Bethpage Parent, Inc., meaning existing shareholders no longer hold equity in the company.
• The reporting person, a Director, no longer holds any beneficial ownership in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4, as it reports a past transaction.

Industry Context

This filing indicates the completion of an acquisition in the biotechnology/life sciences sector, where consolidation through mergers and acquisitions is a common strategic move for companies seeking to expand capabilities, market share, or achieve economies of scale. The specific details of the merger (e.g., strategic rationale for Bethpage Parent, Inc. acquiring Enzo Biochem) are not provided in this Form 4, which focuses solely on the insider's share disposition.

Comparison to Industry Standards

• This Form 4 reports a specific insider transaction related to a merger completion. It does not provide financial results or operational performance data that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The $0.70 per share merger consideration would typically be evaluated against Enzo Biochem's historical stock price, analyst price targets, and valuations of similar companies in comparable M&A transactions, but this filing does not provide that context.

Management Changes

Stakeholder Impact

• Shareholders: Received $0.70 per share in cash, losing their equity stake in the public company.
• Employees: Enzo Biochem continues as a subsidiary, but potential operational or management changes under new ownership are not detailed.
• Customers/Suppliers: Operations are expected to continue under new ownership, but no specific impact is detailed.

Next Steps

• Enzo Biochem Inc. will operate as a wholly-owned subsidiary of Bethpage Parent, Inc.
• The common stock of Enzo Biochem Inc. will no longer be publicly traded.

Key Dates

Recommendation

The filing details the completion of a merger where Enzo Biochem Inc. shares were converted into a cash payment of $0.70 per share. For investors who held shares, the recommendation was to hold until the merger's effective time to receive the cash consideration, as the company is no longer publicly traded. There is no ongoing investment opportunity in Enzo Biochem Inc. common stock.

Keywords

Enzo Biochem, ENZB, Merger, Acquisition, Form 4, Insider Trading, Share Disposition, Cash Consideration, Steven J. Pully, Bethpage Parent Inc